Novozymes Biopharma enters licensing agreement with EpiVax

Published: 6-Jan-2015
Research & Development

To advance treatments for autoimmune diseases


Novozymes Biopharma and EpiVax have entered a licensing agreement for the development of novel treatments for autoimmune diseases. The agreement follows two years of feasibility studies and allows EpiVax to use Novozymes’ albumin technologies to develop immunotherapies.

Novozymes will apply its Veltis technology to EpiVax’s Tregitope technology. Albumin works as a vehicle that transports the active drug ingredients throughout the body and increases the lifespan of the drug in the body to achieve improved patient compliance. As a result, it is possible to modulate half-life of a therapy to offer improved control, enhancing the overall efficacy of treatments.

'We are delighted to move into a licensing agreement with EpiVax in this key area of autoimmune diseases treatment,' said Peter Rosholm, Vice President of Novozymes Biopharma.

'In combination with the technologies and know-how EpiVax holds, Novozymes’ Veltis makes it possible to develop a potential “paradigm-shifting” treatment for autoimmune diseases.'

EpiVax has identified a set of natural peptide sequences, or epitopes, derived from Immunoglobulin G (IgG) that are potent activators of natural T regulatory cells (hence Tregitope). The initial application targeted by the Novozymes and Epivax collaboration will be the development of a recombinant alternative to intravenous immunoglobulin (IVIG) treatment.

'Novozymes’ proven solutions, technical expertise, and reputation as a reliable partner, makes it an ideal company for us to work with as we move our Tregitope immune-modulating technology even closer to clinical trials. After successful feasibility studies, we now move into the next phase, looking to develop a platform for immunomodulation that will change the way that we treat autoimmune diseases, allergy and transplantation,' added Annie De Groot, CEO/CSO of EpiVax.

  • Companies:
  • Novozymes
  • EpiVax
See more

You may also like

Research & Development

Protein properties project aims to guide development of new medicines

Read more
Four-year PIPPI project receives €4m in funding from Horizon 2020

Trending Articles

  1. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation
  2. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  3. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  4. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Protein properties project aims to guide development of new medicines

Four-year PIPPI project receives €4m in funding from Horizon 2020
Research & Development

Novozymes Biopharma enters agreement with leading vaccine company

To conduct research on a novel subunit vaccine complex based on albumin fusion technology
Research & Development

Novozymes Biopharma to offer drug-albumin conjugation platform with ThioLogics

New partnership to offer serum-stable drug-albumin conjugation capability
Research & Development

Novozymes and Janssen to evaluate Veltis half-life extension technology

Series of engineered human albumins could help reduce dosing frequency of drugs
Research & Development

Novozymes Biopharma highlights potential for monthly drug dosing

New data findings demonstrate technological advances for extending serum half-life of drugs bound to albumin
Research & Development

Novozymes and EpiVax to develop autoimmune diseases treatment

Will combine Albufuse half-life extension platform with EpiVax Tregitope therapy
You need to be a subscriber to read this article.
Click here to find out more.
Design & Build

Quicker steps to chirals

Process chemistry groups within pharma companies are adept at solving chirality problems. To enable the practical synthesis of drug molecules for late stage trials and commercial production, they may apply reactions developed elsewhere or invent their own to create cheaper, more efficient and safer large-scale routes to chirally pure APIs
Subscribe now